About the Company
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SYN News
Theriva Biologics Announces Positive Data From Phase 1 Trial Of VCN-01 In Intraocular Retinoblastoma
(RTTNews) - Theriva Biologics Inc. (TOVX) Tuesday announced positive data from the Phase 1 trial evaluating the safety and tolerability of two intravitreal injections of its investigational oncolytic ...
Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript
Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript March 25, 2024 Theriva Biologics, Inc. beats earnings ...
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
About Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas ...
Theriva Biologics Inc TOVX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Synthetic Biologics (NYSEMKT: SYN)
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product ...
Theriva Biologics, Inc.: Theriva Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
Theriva Biologics, Inc. Poster Session Date and Time: Friday, May 10, 2024 at 12:00 p.m. ET About Theriva Biologics, Inc. Theriva Biologics. Forward-Looking Statement This release contains forward ...
Q4 2023 Theriva Biologics Inc Earnings Call
Steven A. Shallcross; CEO, CFO, Treasurer, Corporate Secretary & Director; Theriva Biologics, Inc. Operator And greetings, and welcome to the Theriva Biologics full year 2023 investor conference call.
Theriva Biologics Inc TOVX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript
Greetings, and welcome to the Theriva Biologics Full-Year 2023 Investor Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this conference is being recorded.
Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript
Theriva Biologics, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.41. Theriva Biologics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the ...
Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call Transcript March 25, 2024 Theriva Biologics, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.41. Theriva Biologics, Inc. isn’t one of the 30 most ...
Loading the latest forecasts...